ISPC - iSpecimen Inc. Stock Price, Fair Value and News

0.24USD-0.01 (-4.00%)Delayed

Market Summary

USD0.24-0.01

Delayed

-4.00%

ISPC Stock Price

View Fullscreen

ISPC RSI Chart

ISPC Valuation

Market Cap

2.4M

Price/Earnings (Trailing)

-0.21

Price/Sales (Trailing)

0.23

EV/EBITDA

-0.16

Price/Free Cashflow

-0.47

ISPC Price/Sales (Trailing)

ISPC Profitability

EBT Margin

-56.71%

Return on Equity

-169.81%

Return on Assets

-92.46%

Free Cashflow Yield

-211.9%

ISPC Fundamentals

ISPC Revenue

Revenue (TTM)

10.2M

Rev. Growth (Yr)

-22.38%

Rev. Growth (Qtr)

39.91%

ISPC Earnings

Earnings (TTM)

-11.6M

Earnings Growth (Yr)

-19.34%

Earnings Growth (Qtr)

5.56%

Breaking Down ISPC Revenue

Last 30 days

14.3%

Last 90 days

-46.7%

Trailing 12 Months

-82.7%

How does ISPC drawdown profile look like?

ISPC Financial Health

Current Ratio

0.93

ISPC Investor Care

Shares Dilution (1Y)

10.52%

Diluted EPS (TTM)

-1.29

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	10.2M	0	0	0
2023	11.0M	11.9M	12.1M	10.9M
2022	10.7M	10.4M	10.3M	10.5M
2021	9.4M	10.8M	11.3M	11.1M
2020	0	5.6M	6.9M	8.2M
2019	0	0	0	4.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of iSpecimen Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 14, 2023	bielak benjamin	bought	12,960	0.72	18,000	chief info officer & secretary
May 31, 2023	curley tracy	bought	5,500	1.25	4,400	ceo, cfo and treasurer
Jan 17, 2023	mullan jill	acquired	66,637	1.00	66,637	-
Jan 06, 2023	ianelli christopher	acquired	845	1.00	845	-
Jan 01, 2023	basile joseph j.	acquired	-	-	63.00	-
Jan 01, 2023	mullan jill	acquired	-	-	92.00	-
Jan 01, 2023	ianelli christopher	acquired	-	-	92.00	-
Jan 01, 2023	ross andrew l.	acquired	-	-	125	-
Jan 01, 2023	gullans steven r. ph.d.	acquired	-	-	125	-
Jan 01, 2023	brooks john l. iii	acquired	-	-	125	-

Which funds bought or sold ISPC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-19,428	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	105	-536	10,221	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	3.74	-800	739	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	reduced	-13.14	-5,233	3,526	-%
May 14, 2024	NORTHERN TRUST CORP	unchanged	-	-3,708	3,203	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	reduced	-6.47	-3,000	2,000	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-10,341	8,931	-%
May 13, 2024	UBS Group AG	sold off	-100	-7.00	-	-%
May 10, 2024	VANGUARD GROUP INC	reduced	-42.91	-49,370	17,761	-%
May 10, 2024	BlackRock Inc.	reduced	-0.28	-15,267	13,117	-%

Are Funds Buying or Selling ISPC?

Are funds buying ISPC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ISPC

No. of Funds

Unveiling iSpecimen Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	obf investments, llc	9.3%	841,981	SC 13G/A
Apr 17, 2023	ross andrew l.	797%	1,336,730	SC 13D
Feb 13, 2023	obf investments, llc	9.4%	841,981	SC 13G/A
Jan 12, 2023	empery asset management, lp	4.68%	437,500	SC 13G/A
Dec 27, 2022	wolf james g.	9.03%	790,730	SC 13G/A
Sep 28, 2022	wolf james g.	6.13%	544,250	SC 13G
Feb 14, 2022	obf investments, llc	9.6%	841,981	SC 13G
Feb 14, 2022	bleichroeder lp	3.41%	342,180	SC 13G/A
Feb 07, 2022	ross andrew l.	15.23%	1,329,759	SC 13G

Recent SEC filings of iSpecimen Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report
Apr 11, 2024	8-K	Current Report
Mar 28, 2024	PRE 14A	PRE 14A
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	3	Insider Trading
Mar 14, 2024	8-K	Current Report
Mar 13, 2024	10-K	Annual Report
Mar 05, 2024	8-K	Current Report

Peers (Alternatives to iSpecimen Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

iSpecimen Inc. News

Latest updates

iSpecimen Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Revenue	39.9%	2,289,993	1,636,781	2,777,751	3,501,769	2,950,197	2,827,483	2,583,412	2,606,809	2,518,660	2,549,086	2,718,534	2,903,876	2,963,807	2,717,731	2,250,147	1,504,569	-
Costs and Expenses	-2.9%	5,290,513	5,446,119	4,971,831	5,186,963	5,492,620	5,103,171	5,684,471	4,923,695	4,877,048	4,544,084	4,177,607	4,432,407	3,906,451	3,652,181	2,973,226	1,809,575	-
S&GA Expenses	-36.6%	665,941	1,050,921	897,433	977,748	962,169	914,725	832,625	950,563	747,432	732,658	513,107	647,592	529,387	477,666	506,641	367,617	-
EBITDA Margin	-6.5%	-0.55	-0.52	-0.45	-0.46	-0.50	-0.52	-0.54	-0.53	-0.42	-0.33	-0.27	-0.12	-0.24	-0.31	-	-	-
Interest Expenses	0.0%	4,465	4,466	4,465	3,535	3,535	-	58,591	42,273	38,048	40,133	75,922	1,133,479	853,147	579,098	469,477	459,005	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-145	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-1,553,023	-1,394,914	-	-1,593,544	-1,246,469	-174,237	-
EBT Margin	-6.5%	-0.57	-0.53	-0.48	-0.49	-0.53	-0.55	-0.56	-0.56	-0.54	-0.52	-0.51	-0.41	-0.49	-0.57	-	-	-
Net Income	5.6%	-2,902,117	-3,072,961	-2,111,101	-3,483,614	-2,431,812	-2,159,681	-3,095,690	-2,606,809	-2,383,742	-2,050,387	-1,553,023	-1,394,914	-3,963,491	-1,593,544	-1,246,469	-174,092	-
Net Income Margin	-11.0%	-1.13	-1.02	-0.84	-0.94	-0.94	-0.97	-0.99	-0.83	-0.69	-0.80	-0.75	-0.76	-0.74	-0.57	-0.69	-	-
Free Cashflow	-703.1%	-2,081,499	345,141	-1,639,506	-1,699,056	-2,833,607	-207,354	-2,256,389	-1,978,061	-1,375,916	-1,319,709	-6,080,166	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-20.9%	12,514	15,819	16,295	17,570	21,939	24,618	27,940	30,397	33,287	35,720	17,622	19,605	12,907	6,210	4,215
Current Assets	-35.8%	5,286	8,239	9,127	10,971	15,960	19,676	24,236	27,131	30,151	32,948	14,899	16,919	-	3,472	1,581
Cash Equivalents	-10.8%	2,090	2,344	2,722	2,005	3,763	15,309	20,658	23,691	26,099	27,739	9,791	13,184	355	696	54.00
Net PPE	-5.4%	121	128	146	164	195	226	19.00	24.00	28.00	33.00	45.00	56.00	-	76.00	120
Liabilities	-6.2%	5,701	6,078	3,589	2,860	3,855	4,308	5,516	5,100	5,620	5,928	5,531	8,926	15,620	22,315	15,760
Current Liabilities	-5.8%	5,701	6,049	3,517	2,860	3,855	4,281	2,833	2,029	2,047	2,505	2,103	5,926	-	22,136	15,760
Shareholder's Equity	-30.1%	6,813	9,741	12,706	14,711	18,084	20,309	22,423	25,298	27,667	29,792	12,091	10,679	-	-	-
Retained Earnings	-4.9%	-62,266	-59,364	-56,291	-54,180	-50,697	-48,265	-46,105	-43,009	-40,403	-38,019	-35,969	-34,415	-	-29,057	-24,405
Additional Paid-In Capital	0.0%	69,079	69,104	68,996	68,890	68,762	68,574	68,528	68,307	68,070	67,810	48,059	45,095	-	1,780	1,687
Shares Outstanding	4.3%	9,470	9,083	9,074	9,063	9,022	8,926	8,822	8,794	8,765	8,733	3,190	1,274	936	936	-
Float	-	-	-	-	10,362	-	-	-	13,041	-	-	-	27,429	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-700.4%	-2,072	345	-1,633	-1,693	-2,825	-207	-2,256	-1,978	-1,375	-1,319	-6,080	-3,142	-126	-24.65	-319	-	-
Share Based Compensation	-13.1%	94.00	108	106	125	121	45.00	220	229	184	172	400	28.00	22.00	12.00	29.00	-	-
Cashflow From Investing	368.0%	1,937	-723	2,351	-67.97	-8,788	-1,641	-772	-438	-339	-304	-290	-228	-214	-236	-273	-	-
Cashflow From Financing	-Infinity%	-118	-	-	3.00	68.00	-3,499	-4.97	8.00	75.00	19,572	2,977	-	-	-	250	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ISPC Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Statements of Operations
Revenue	$ 2,289,993	$ 2,950,197
Operating expenses:
Cost of revenue	1,000,006	1,146,912
Technology	911,967	834,407
Sales and marketing	665,941	962,169
Supply development	197,839	275,246
Fulfillment	410,854	455,531
General and administrative	2,103,906	1,818,355
Total operating expenses	5,290,513	5,492,620
Loss from operations	(3,000,520)	(2,542,423)
Other income, net
Interest expense	(4,465)	(3,535)
Interest income	30,498	114,263
Other income (expense), net	72,370	(117)
Total other income, net	98,403	110,611
Net loss	(2,902,117)	(2,431,812)
Unrealized loss on available-for-sale securities	(799)	18,843
Total other comprehensive income (loss)	(799)	18,843
Comprehensive loss	$ (2,902,916)	$ (2,412,969)
Net loss per share
Basic (in dollars per share)	$ (0.32)	$ (0.27)
Diluted (in dollars per share)	$ (0.32)	$ (0.27)
Weighted average shares of common stock outstanding
Basic (in shares)	9,132,460	8,980,898
Diluted (in shares)	9,132,460	8,980,898

ISPC Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,089,891	$ 2,343,666
Available-for-sale securities	466,493	2,661,932
Accounts receivable - unbilled	1,978,144	2,212,538
Accounts receivable, net of allowance for doubtful accounts of $718,821 and $520,897 at March 31, 2024 and December 31, 2023, respectively	437,424	728,388
Prepaid expenses and other current assets	313,999	292,079
Total current assets	5,285,951	8,238,603
Property and equipment, net	120,873	127,787
Internally developed software, net	6,065,770	6,323,034
Other intangible assets, net	860,366	908,255
Operating lease right-of-use asset	153,340	193,857
Security deposits	27,601	27,601
Total assets	12,513,901	15,819,137
Current liabilities:
Accounts payable	3,560,474	3,925,438
Accrued expenses	1,710,815	1,540,607
Operating lease - current obligation	156,703	167,114
Deferred revenue	272,681	415,771
Total current liabilities	5,700,673	6,048,930
Operating lease long - term obligation		29,130
Total liabilities	5,700,673	6,078,060
Commitments and contingencies (See Note 8)
Stockholders' equity
Common stock, $0.0001 par value, 200,000,000 shares authorized, 9,501,112, and 9,470,112 outstanding at March 31, 2024 and 9,114,371 issued and 9,083,371 outstanding at December 31, 2023	947	908
Additional paid-in capital	69,079,341	69,104,313
Treasury stock, 31,000 shares at March 31, 2024 and December 31, 2023, at cost	(172)	(172)
Accumulated other comprehensive income	41	840
Accumulated deficit	(62,266,929)	(59,364,812)
Total stockholders' equity	6,813,228	9,741,077
Total liabilities and stockholders' equity	$ 12,513,901	$ 15,819,137

About iSpecimen Inc.

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

CEO	Ms. Tracy Wilson Curley
WEBSITE	https://ispecimen.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	75

iSpecimen Inc. Frequently Asked Questions

What is the ticker symbol for iSpecimen Inc.? What does ISPC stand for in stocks?

ISPC is the stock ticker symbol of iSpecimen Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of iSpecimen Inc. (ISPC)?

As of Fri May 17 2024, market cap of iSpecimen Inc. is 2.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ISPC stock?

You can check ISPC's fair value in chart for subscribers.

What is the fair value of ISPC stock?

You can check ISPC's fair value in chart for subscribers. The fair value of iSpecimen Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of iSpecimen Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ISPC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is iSpecimen Inc. a good stock to buy?

The fair value guage provides a quick view whether ISPC is over valued or under valued. Whether iSpecimen Inc. is cheap or expensive depends on the assumptions which impact iSpecimen Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ISPC.

What is iSpecimen Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ISPC's PE ratio (Price to Earnings) is -0.21 and Price to Sales (PS) ratio is 0.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ISPC PE ratio will change depending on the future growth rate expectations of investors.